

West Virginia Medicaid Drug Utilization Review Board Minutes

November 15, 2017

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Ernest Miller, DO
Michael Ballow, PharmD
John Vanin, MD
John Guilfoose, MD (via phone)
Scott Brown, RPh (via phone)
Kate Forman, PharmD (via phone)
Christopher Booth, PharmD (via phone)

Members Absent:

Michael Lonsinger, PharmD
Myra Chiang, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Lori Moles, RPh, Staff Pharmacist
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Goold Health Systems
Taylor DeRuiter, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:06 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM September 20, 2017 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

A. **Speakers**

1. Ahmad Nessar - Amgen,

B. **PDL Prior Authorization Criteria (Attachment B)**

1. **PCSK9 Inhibitors** –The Board agreed to amend the criteria previously presented to add specific examples of non-statin therapies. A motion to approve the document as amended was made, seconded, and passed.
2. **Emflaza** - A motion to approve the criteria as presented was made, seconded, and passed.

IV. NEW BUSINESS

A. **Speakers**

- | | | | |
|----|--------------------|-----------------------------|--------------------------------|
| 1. | Dr. Louis Yancich | New Life Clinics | Suboxone |
| 2. | Amber Tichnell | Nat'l Hemophilia Foundation | Eucrisa |
| 3. | Maria Schiame | Shire | Advate, Adynovate,
Vonvendi |
| 4. | Andrea Wilson | Boehinger | Jardiance |
| 5. | Joseph Loftus | Novo Nordisk | Victoza |
| 6. | Danny Westmoreland | Physician Advocate | Belsomra |

B. **Updates from the October 25, 2017 Pharmacy & Therapeutics Committee Meeting**

1. Dr. Labus and the Board reviewed the updates from the October 25 P&T meeting (Attachment A). No criteria changes were requested beyond those presented in section IV-C of this document.

C. **PDL Prior Authorization Criteria (Attachment B)**

1. **Antihemophilia Factor Agents** – A motion to approve the criteria as presented was made, seconded, and passed.
2. **Antiparkinson's Agents** – A motion to approve the criteria as presented was made, seconded, and passed.
3. **Latuda** – A motion to approve the criteria as presented was made, seconded, and passed.
4. **Bone Resorption Suppression and Related Agents** – A motion to approve the criteria as presented was made, seconded, and passed.
5. **COPD Agents & Stiolto Respimat** – A motion to approve the criteria as presented was made, seconded, and passed.
6. **Enbrel/Humira** – A motion to approve the criteria as presented was made, seconded, and passed.
7. **Growth Hormone** – A motion to approve the criteria as presented was made, seconded, and passed.
8. **Hepatitis B Treatments** – A motion to approve the criteria as presented was made, seconded, and passed.
9. **Hypoglycemics, Biguanides** – A motion to approve the criteria as presented was made, seconded, and passed.
10. **GLP-1 Agonists** – A motion to approve the criteria as presented was made, seconded, and passed.

11. **SGLT-2 inhibitors** – A motion to approve the criteria as presented was made, seconded, and passed.
12. **Immunomodulators, Atopic Dermatitis class criteria** – A motion to approve the criteria as presented was made, seconded, and passed.
13. **Dupixent** – A motion to approve the criteria as presented was made, seconded, and passed.
14. **Kynamro** – A motion to approve the criteria as presented was made, seconded, and passed.
15. **Juxtapid** – A motion to approve the criteria as presented was made, seconded, and passed.
16. **NSAIDS** – A motion to approve the criteria as presented was made, seconded, and passed.
17. **Cotempla & Mydayis** – A motion to approve the criteria as presented was made, seconded, and passed.
18. **Cinryze & Haegarda** – A motion to approve the criteria as presented was made, seconded, and passed.
19. **Non-sedating antihistamines** – A motion to approve the criteria as presented was made, seconded, and passed.

D. Suboxone: A motion to remove criteria requiring that all patients taking Suboxone be locked-in to a single pharmacy was made, seconded, and passed.

V. REPORTS

- A. Molina Quarterly Report** – Eric Sears presented an overview of the Molina 2017 Third Quarter Report (Attachment C). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the Third Quarter 2017. Mark Garofoli presented an overview of the Safe and Effective Management of Pain Guidelines (SEMP).
- C. Health Information Designs** – Taylor DeRuiter presented an overview of the Third Quarter 2017 retrospective drug utilization activity (Attachment D). The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. None

VII. NEXT MEETING AND ADJOURNMENT

- A.** A motion to adjourn the meeting was made, seconded, and passed.
- B.** The meeting concluded at 6:20 p.m. EDT.
- C.** The next meeting will be Wednesday, February 28, 2018 from 4:00 p.m.–6:00 p.m. and located at WVDHR.

Submitted by:

Taylor DeRuiter, PharmD, Health Information Designs